Fairvalue-Calculator Fairvalue-Calculator
EN DE

KDA Group (KDA) Fair Value & Analysis

Healthcare · CA · Market cap C$14.0M

PriceC$0.0750
Fair ValueC$0.0263
Upside-65.0%
Quality80/100
Evidence: Low

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

KDA Group (KDA) currently trades at C$0.0750, while our model-based Fair Value estimate is C$0.0263 — implying the stock looks roughly 65.0% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

KDA Group Inc., together with its subsidiaries, provides technological and operational efficiency solutions for both the general and specialized health sectors in Canada. The company offers Adherize+, which is an intelligent patient engagement platform designed to monitor treatment adherence and provide tailored interventions; Medherize, a specialized module of Adherize+, focuses on patients undergoing complex therapies such as oral oncology treatments; KRx is an advanced electronic prescription platform for medical clinics; and CareMedic is digital health record and care coordination platform. The company was formerly known as AlliancePharma Inc. and changed its name to KDA Group Inc. in February 2017. KDA Group Inc. is headquartered in Thetford Mines, Canada.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is KDA Group (KDA) undervalued?
As of Jun 26, 2026, our model estimates a fair value of C$0.0263 versus a price of C$0.0750 — about −65% (overvalued). Model-based estimate, not financial advice.
What is the fair value of KDA?
Our 21-model fair value for KDA Group is C$0.0263 (as of Jun 26, 2026), built from audited fundamentals. The current price is C$0.0750.
What is the quality score of KDA?
KDA Group has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.